BI-furc-Asian: Boehringer's tiered strategy to get novel drugs to emerging markets
This article was originally published in Scrip
Professor Dr Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim, believes that as part of an improved pricing strategy across the industry there was a need to develop a tiered pricing system which ensures better access to novel medicines in some emerging markets.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.